Importantly, the complex pathophysiology of progressive MS suggests that combination therapies targeting different processes would represent the “ideal” therapeutic approach, as anticipated for GPR17 (Coppolino et al., 2018; Lecca et al., 2020). This evidence concerns the gene GPR17 and myeloid sarcoma.